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Abstract 
Potentially adverse human and environmental effects due to 
hormone mimicry of environmental estrogens are a matter of 
current concern. Environmental estrogens belong to the so-
called endocrine active compounds (EAC) and may alter 
signalling processes of the endocrine system leading to a 
broad range of effects during fetal and postnatal develop-
ment, puberty, adulthood, and aging. A number of synthetic 
chemicals as well as several plant-derived compounds, so-
called phytoestrogens, are known to have weak estrogenic 
activity.  
The present study is part of the risk assessment of the weak 
environmental estrogens daidzein and bisphenol A. The 
isoflavone daidzein is an important phytoestrogen with 
respect to dietary exposure (soy beans and soy products) 
whereas bisphenol A is an industrial chemical that occurs at 
much lower concentrations as a contaminant in food. The 
toxicokinetics of these compounds in female pregnant and 
non-pregnant DA/Han rats after single intravenous 
application were compared by the use of the Mann-Whitney-
U-statistic.  
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1. Introduction 
 
So-called endocrine active compounds (EAC) in general and environmental 
estrogens in particular are still a matter of concern (Damstra et al., 2002; 
Degen and Bolt, 2000a; European Community, 1997). EACs may alter the 
signalling processes of the endocrine system that is responsible for the 
regulation and the coordination of physiological functions during fetal and 
postnatal development, puberty, adulthood and aging. The signalling 
processes depend on concentrations of biologically active levels of 
hormones which are controlled by biosynthesis, metabolizing enzymes and 
binding proteins (Barton and Andersen, 1998; National Research Council, 
1999).  
The particular class of EACs we are investigating are environmental 
estrogens which have more or less similar effects as steroid estrogens have. 
The estrogenic effects are primarily due to the binding to the hormone 
receptors although with much lower affinity, but may also arise by other 
mechanisms (Nilsson et al., 2001). 
There is consensus that endocrine active compounds, at sufficient levels, 
can interfere with the hormonal regulation and lead to potentially adverse 
effects. Observations leading to concerns have been made in wildlife in 
some regions with high exposure to synthetic environmental estrogens 
and/or anti-androgens: This resulted in decreased fertility of alligators, 
fishes and birds as well as feminisation effects and demasculinization of 
mammals, birds and fishes (Tyler et al., 1998; Vos et al., 2000). Severe 
adverse health effects occurred also in humans exposed prenatally to high 
doses of the potent estrogen diethylstilbestrol (Golden et al., 1998). 
However, controversy surrounds the question of risks associated with the 
actual (low) levels of exposure to environmental agents with much weaker 
hormonal activity (DGPT, 1999; Safe, 2000; Sharpe and Irvine, 2004). 
 
Sources of human exposure to environmental estrogens are naturally 
occurring dietary compounds as well as the release of synthetic chemicals: 
Examples are plant-derived compounds, so-called phytoestrogens, for 
instance the isoflavones daidzein and genistein that are found in soy beans 
and soy products. Examples of synthetic agents are pesticides like DDT or 
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industrial chemicals like alkylphenols, bisphenol A or PCBs which give rise 
to residues in foods (Mäkelä et al., 1999; Degen, 2004). The present study 
considers the isoflavone daidzein and the industrial chemical bisphenol A, 
used e.g. in the production of plastic coatings in the food packaging industry 
(EU Commission, 2002). 
 
Human exposure to these prototypical compounds is mainly via food and 
drinking water. Exposure to phytoestrogens depends much on dietary habits, 
as the main sources are soybeans and soy products. So in Japan, for 
instance, the consumption of soybean products is 30 to 50 times higher than 
that in Western Europe or the United States (Degen and Bolt, 2000b; Degen 
et al., 2002b). Interestingly, also beneficial effects of dietary phytoestrogens 
have become a major focus in medicine, and these compounds are now 
popular as alternative hormone replacement therapy (Setchell and Cassidy, 
1999). But, a toxicological risk assessment for environmental estrogens has 
to be unbiased with respect to the origin of compounds. It needs to consider 
the following aspects:  
• Aside from synthetic xenoestrogens humans are mainly exposed to 
environmental estrogens of natural origin (phytoestrogens). 
•  A given compound may have agonistic (estrogenic) or anti-agonistic 
(anti-estrogenic) effects depending on the dose, the target organ and 
the endocrine state of the whole organism (Mäkelä et al., 1999).  
• Endocrine/receptor-mediated effects are not automatically adverse 
effects. 
• Exogenous exposure to environmental estrogens has to be consi-
dered on the background level of endogenous estrogens (DGPT, 
1999).  
In assessing the risk of synthetic estrogens it is important to take the 
exposure to phytoestrogens into account along with information on toxico-
dynamics and toxicokinetics (Bolt et al., 2001; Bolt and Degen, 2002; 
Degen et al., 2002c). In other words, effects of a compound will depend 
upon its properties (receptor affinity, potency) and the dose, but, also on its 
fate in the organism, i.e. the biologically active fraction in a target tissue 
upon absorption, distribution, metabolism and elimination. Studies on the 
toxicokinetics of daidzein and of bisphenol A in adult female rats revealed 
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extensive metabolism (conjugation) by phase-II enzymes for both 
compounds (Janning et al., 2000; Upmeier et al., 2000) and bioavailabilities 
of a similar order of magnitude (Selinski and Degen, 2003). Yet, the kinetics 
in non-pregnant rats may differ from those in pregnant animals: On the one 
hand, phase-II metabolism may be slower (or faster) in pregnant rats result-
ing in higher (or lower) levels of unconjugated xeno-/phytoestrogen in their 
blood than in non-pregnant animals. On the other hand, part of a given dose 
can pass the placenta and distribute into the fetal compartment which may 
result in lower maternal plasma levels. Thus, along with a direct analysis of 
the compounds in rat fetuses to investigate transplacental transfer of 
daidzein and bisphenol A, it was of interest to compare their blood levels in 
pregnant and non-pregnant rats.  
 
 
 
 
 
2. Data  
 
The present data sets arise from the following study on xenoestrogens at the 
Institut für Arbeitsphysiologie an der Universität Dortmund (IfADo).  
First, female non-pregnant DA/Han rats were given the compound of 
interest intravenously at a low dosing level of 10 mg/kg bodyweight. The 
used estrogen mimetic compounds were daidzein and bisphenol A. The 
plasma concentration was determined at several time-points per animal. 
Individual samples were available 3 to 6 times per animal. The experimental 
design is given in table 2. For details see Janning et al. (2000) and Upmeier 
et al. (2000). Note, that each animal is observed at a subset of sampling 
times. The real sampling times may vary across the planned ones but are 
usually recorded.  
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Table 2. Experimental design of the xenoestrogen study with non-pregnant 
DA/Han rats, j* is the index of the sampling times tj* in minutes since 
intravenous application of 10 mg/kg bodyweight daidzein or bisphenol A, nj* 
is the respective number of observations.  
Substance j* tj* nj* 
1 1 2 
2 5 3 
3 10 3 
4 20 2 
5 40 3 
6 60 2 
7 120 2 
8 180 3 
9 240 3 
10 360 4 
11 480 4 
12 1440 5 
13 1920 1 
Daidzein 
14 2880 1 
1 1 2 
2 5 3 
3 10 3 
4 20 2 
5 30 1 
6 40 3 
7 60 3 
8 120 3 
9 180 3 
10 240 3 
11 360 3 
12 480 3 
13 1440 2 
14 1920 4 
Bisphenol A 
15 2880 2 
 
Second, pregnant DA/Han rats were given the compound of interest, 
daidzein or bisphenol A, intravenously at a low dosing level of 10 mg/kg 
bodyweight. The plasma and further tissue concentrations were determined 
once per animal at sacrifice. Plasma concentrations of a few animals were 
observed at an early point of time. For these animals we were able to 
ascertain that the dose was indeed given intravenously and not 
paravenously. Such injection errors can occur because of the heavy pigmen-
tation of the DA/Han rats and result in much lower blood levels. 
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The experimental design is given in table 3. For details see Degen et al. 
(2002a) and Bolt et al. (2002) or Moors et al. (2003, 2004, and manuscript 
in preparation).  
The real sampling times may vary across the planned ones but are usually 
recorded.  
 
Table 3. Experimental design of the xenoestrogen study with pregnant 
DA/Han rats, j** is the index of the sampling times tj** in minutes since 
intravenous application of 10 mg/kg bodyweight daidzein or bisphenol A, 
nj** is the respective number of observations.  
Substance j** tj** nj** 
1 5 4 
2 10 4 
3 20 4 
4 40 4 
Daidzein 
5 120 4 
1 5 11 
2 10 10 
3 20 6 
4 30 6 
5 40 5 
6 120 4 
Bisphenol A 
7 360 4 
 
 
 
 
 
3. Models and Methods 
 
The main interest of this analysis is focused on the impact of a pregnancy on 
the toxicokinetic behaviour of estrogen mimetic compounds. Here, we have 
to deal with the difficulty of different experimental designs: Short 
concentration-time curves with very few observations at each time-point, in 
case of non-pregnant rats, and a destructive design with many variables 
observed at a subset of sampling times, in case of the pregnant rats. 
Moreover, the tissue data recorded from the pregnant animals after 
administration of either daidzein or bisphenol A may be used to obtain 
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information about differences between the toxicokinetics of the two 
compounds.  
 
 
3.1 Comparison of the toxicokinetics of pregnant and non-
pregnant rats 
Comparing the toxicokinetics of the pregnant and non-pregnant rats after 
intravenous application of either daidzein or bisphenol A we had to take the 
different experimental design into account. Individual concentration-time 
curves were only available for the non-pregnant rats. In case of the pregnant 
rats each individual was observed just one time for daidzein or two times at 
most for some animals after application of bisphenol A. Furthermore 
samples were taken just on a subset of the sampling times we had for the 
non-pregnant rats. The last samples from the pregnant rats were taken after 
120 minutes in case of daidzein and after 360 minutes in case of bisphenol 
A instead of 2880 minutes in case of non-pregnant animals.  
Thus, observations from both populations, pregnant and non-pregnant rats, 
were compared separately for each sampling time tj, j = 1, . . ., J, by the use 
of the Mann-Whitney-U-test which is equal to the Wilcoxon rank sum test 
(see Büning and Trenkler, 1994; Hollander and Wolfe, 1999).   
∑
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In case of large samples  
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where K denotes the number of tied groups and tk is the size of the kth tied 
group. An untied observation is considered to be a tied group of size 1.  
 
Reject H0 if  
a. One-Sided Upper-Tail-Test 
 reject,not  do otherwise   ;* αzW ≥      (9) 
b. One-Sided Lower-Tail-Test 
reject,not  do otherwise   ;* αzW −≤              (10) 
c. Two-Sided Test 
reject not  do otherwise   ;2/* αzW ≥             (11) 
For the present analysis the one-sided tests were applied. 
 
3.2 Comparison of the toxicokinetics of pregnant DA/Han 
rats after application of different xenoestrogenes 
For comparison of the toxicokinetic behaviour of the two chemicals we 
calculated the ratios of the different tissue concentrations, their medians and 
the probability of the Wilcoxon rank sum test statistic assuming that there 
are no differences in the toxicokinetic behaviour of daidzein and 
bisphenol A in pregnant DA/Han rats.  
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4. Results 
 
A chemical’s distribution among tissues depends on the blood flow, the free 
(non-protein-bound) fraction and its tissue:blood partition coefficient. 
Csanady et al. (2002) measured higher fat:blood partition coefficients for 
bisphenol A (3.3) than for daidzein (0.3) in in vitro studies, but, all partition 
coefficients in non-adipose tissues (liver, kidney, placenta, muscle, etc.) 
were similar for both compounds (average values: BPA 1.4, DA 1.2). 
Despite the more lipophilic nature of bisphenol A the two compounds 
daidzein and bisphenol A seem to behave rather similar in vivo comparing 
pregnant and non-pregnant DA/Han rats. 
 
 
4.1 Comparison of pregnant and non-pregnant DA/Han rats 
Comparing the plasma concentrations of pregnant and non-pregnant 
DA/Han rats reveals that the maternal blood levels are not consistently 
higher or lower over the complete duration of the experiment for both 
chemicals. The levels for daidzein and bisphenol A aglycones are depicted 
below (at different concentration and time scales to show all data points; see 
figures 1-3 for daidzein and 4-6 for bisphenol A).  
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Figure 1. Plasma concentration in ng/ml in pregnant and non-pregnant 
DA/Han rats, time in minutes since application of daidzein (overview). 
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Figure 2. Plasma concentration in ng/ml in pregnant and non-pregnant 
DA/Han rats, time in minutes since application of daidzein (zoomA). 
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Figure 3. Plasma concentration in ng/ml in pregnant and non-pregnant 
DA/Han rats, time in minutes since application of daidzein (zoomB). 
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Figure 4. Plasma concentration in ng/ml in pregnant and non-pregnant 
DA/Han rats, time in minutes since application of bisphenol A (overview). 
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Figure 5. Plasma concentration in ng/ml in pregnant and non-pregnant 
DA/Han rats, time in minutes since application of bisphenol A (zoomA). 
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Figure 6. Plasma concentration in ng/ml in pregnant and non-pregnant 
DA/Han rats, time in minutes since application of bisphenol A (zoomB). 
 
 
The results of the Wilcoxon rank sum test for differences in the plasma 
levels in pregnant and non-pregnant rats after intravenous application of 
10 mg/kg bodyweight daidzein are given in table 4. Comparing the plasma 
levels it seems as if the concentration of daidzein aglycone is lower in 
pregnant rats than in non-pregnant rats in the beginning of the experiment. 
Differences at an α level of significance of 0.05 and 0.1, respectively, are 
detected at sampling times of 5 and 20 minutes. For tj = 10, 40 and 120 
minutes there were no clear difference though the plasma levels seem to be 
higher in pregnant rats after 120 minutes.  
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Table 4. Results of the Wilcoxon rank sum test, sampling times in minutes 
and plasma concentration of daidzein aglycone in ng/ml.  
Non-pregnant Pregnant 
Rat 
No. 
t in 
min Concentration 
Rat 
No 
t in 
min Concentration 
Wilcoxon rank-sum test 
23 5 7602 22A 5 875 Reject H0, α = 0.05 
71 5 10172 16A 5 1140   
8 5 18248 12A 5 1712   
      9A 5 3020   
68 10 5057 14B 10 2240 Do not reject H0 
69 10 7592 4B 10 3290 α = 0.1/ 0.05 
12 10 17033 6B 10 4240   
      2B 10 14780   
16 23 2143 37E 20 404 Reject H0,  α = 0.1 
63 20 3071 38E 20 511   
     39E 20 897   
      36E 20 1422   
23 41 390 10C 40 45 Do not reject H0 
8 44 447 8C 40 123 α = 0.1/ 0.05 
71 40 674 7C 40 345   
      15C 40 624   
63 120 45 5D 120 148 Do not reject H0 
16 122 191 1D 120 173 α = 0.1/ 0.05 
     3D 120 359   
      13D 120 593   
 
The results for bisphenol A are quite similar (see table 5).  
Comparing the plasma levels it seems as if the concentration of bisphenol A 
aglycone is lower in pregnant rats than in non-pregnant rats in the beginning 
of the experiment. Differences at an α level of significance of 0.05 are 
detected at sampling times of 5 and 10 minutes. For tj = 20, 40, 120 and 360 
minutes there were no clear difference though the plasma levels seem to be 
higher in pregnant rats after 120 minutes.  
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Table 5. Results of the Wilcoxon rank sum test, sampling times in minutes 
and plasma concentration of bisphenol A aglycone in ng/ml.  
Non-pregnant Pregnant 
Rat 
No. 
t in 
min Concentration 
Rat 
No. 
t in 
min Concentration 
Wilcoxon rank-sum test 
36 7 8271 18 5 327 Reject H0, α = 0.05 
34 5 9085 64 5 444   
35 6 9643 21 6 664   
     27 5 918   
     53 5 1774   
     59 5 2098   
     67 5 3138   
     65 6 4118   
     25 5 5374   
     58 5 6066   
      62 5 11970   
47 11 2928 20 10 462 Reject H0, α= 0.05 
46 12 4496 31 10 499   
25 10 6209 33 10 697   
     29 10 852   
     34 10 1093   
     60 10 1500   
     55 10 1760   
     66 11 1896   
     57 11 2332   
      54 10 2367   
55 21 887 47 21 140 Do not reject H0   
44 20 2403 53 18 640 α = 0.05/0.1 
     51 22 1129   
     40 21 1643   
     46 20 2058   
      62 20 3350   
36 39 358 19 40 63 Do not reject H0   
34 45 795 35 40 684 α = 0.05/0.1 
35 40 1916 32 39 810   
     30 41 1017   
      28 40 1607   
44 120 63 17 123 54.9 Do not reject H0,  
42 120 97 23 121 170.2 α = 0.05/0.1 
55 118 132 26 120 248.4   
      24 120 327.3   
46 363 24 44 360 8.1 Do not reject H0   
47 370 39 43 361 39.1 α = 0.05/0.1 
25 364 44 42 358 43.0   
      45 361 81.1   
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4.2 Comparison of the tissue concentration ratios in 
pregnant rats 
Ratios of the different tissue concentrations were calculated for each animal 
and compared for the two experimental groups of pregnant DA/Han rats 
which received an intravenous application of 10 mg/kg bodyweight daidzein 
or bisphenol A.  
 
Table 6. Medians of the ratios of tissue concentration after application of 
either daidzein or bisphenol A, where agly. denotes aglycone, mat. 
maternal, fet. fetal, and fetus denotes the homogenate without liver. 
plasma 
agly.: 
mat. 
liver: uterus: placenta: kidney: fet. liver: 
 
time 
in min plasma 
total 
plasma 
total 
plasma 
total 
plasma 
total 
plasma 
total 
plasma 
total 
5 0.97 1.53 0.14 0.13 1.44 0.06 
10 0.56 3.21 0.51 0.32 1.46 0.12 
20 0.44 3.70 0.56 0.34 1.92 0.13 
40 0.20 3.58 0.88 0.54 1.97 0.14 D
ai
dz
ei
n 
120 0.39 2.85 0.81 0.36 1.49 0.15 
5 0.75 3.26 0.87 0.56 3.29 0.48 
10 0.71 3.71 0.91 0.78 2.75 0.77 
20 0.48 2.89 0.98 0.92 2.39 1.27 
30 0.42 2.76 2.45 1.25 1.93 1.27 
40 0.45 5.26 1.03 1.02 1.24 0.84 
120 0.28 6.98 1.23 1.12 1.22 1.44 
B
PA
 
360 0.05 5.72 1.96 1.29 1.18 1.85 
fetus: placenta: fet. liver: fetus: fet. liver: fet. liver: 
 
time 
in min plasma 
total uterus placenta placenta mat. liver fetus 
5 0.08 0.40 0.45 0.38 0.03 1.07 
10 0.10 0.60 0.41 0.32 0.04 1.26 
20 0.11 0.63 0.37 0.31 0.04 1.15 
40 0.13 0.61 0.24 0.21 0.04 1.07 D
ai
dz
ei
n 
120   0.42 0.19   0.03   
5 0.23 0.66 1.06 0.56 0.14 2.18 
10 0.42 1.02 0.96 0.49 0.20 1.91 
20 0.71 0.56 0.93 0.63 0.34 1.68 
30 0.92 0.59 1.04 0.73 0.42 1.19 
40 0.61 0.96 0.59 0.52 0.15 1.21 
120 0.65 0.77 1.28 0.47 0.18 2.01 
B
PA
 
360 1.52 0.75 1.29 1.23 0.33 1.09 
 
Changes in ratios between plasma and tissues over time reflect the decline 
in blood levels of the xeno-/phytoestrogen and its distribution to other 
maternal and fetal compartments. For instance, the ratios are highest for 
maternal liver due to an efficient hepatic extraction of the compounds from 
the circulation, followed by kidney, the main organ for their excretion. The 
ratios for plasma / fetal liver are lower and similar to those of other tissues 
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(e.g. uterus, placenta); but they are clearly higher for bisphenol A than for 
daidzein. This is probably due to the higher lipophilicity of bisphenol A 
which is thought to facilitate a rapid distribution to uterus, placenta and 
fetus. Differences are detected mainly at early sampling times at in the 
plasma ratios. The fetus-plasma or placenta-plasma ratios show differences 
during up to sampling times of 40 or 120 minutes, respectively. 
 
Table 7. P-values based of the Wilcoxon rank-sum test for differences 
between the tissue ratios in daidzein or bisphenol A treated pregnant 
DA/Han rats, where agly. denotes aglycone, mat. maternal, fet. fetal, and 
fetus denotes the homogenate without liver. 
plasma 
agly.: 
mat. 
liver: uterus: placenta: kidney: fet. liver: 
tim
e 
plasma 
total 
plasma 
total 
plasma 
total 
plasma 
total 
plasma 
total 
plasma 
total 
5 0.0616 0.0128 0.0054 0.0066 0.0281 0.0404 
10 0.0897 0.6434 0.0206 0.0055 0.0087 0.0105 
20 0.5224 0.2568 0.0233 0.089 0.4497 0.0143 
40 0.1416 0.4624 0.6242 0.05 0.4624 0.0143 
120 0.7728 0.0209 0.1489 0.0433 0.5637 0.1573 
fetus: placenta: fet. liver: fetus: fet. liver: fet. liver: 
tim
e 
plasma 
total uterus placenta placenta mat. liver fetus 
5 0.0676 0.7341 0.3798 0.4334 0.079 0.2752 
10 0.0055 0.217 0.0881 0.0641 0.0105 0.3938 
20 0.0201 0.8501 0.0881 0.0201 0.0143 0.2938 
40 0.0143 0.05 0.1416 0.2207 0.0143 0.6242 
120   0.1489 0.1573   0.1573   
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5. Discussion 
 
As mentioned already above (p.3-4), it was the primary goal of our 
toxicokinetic studies in pregnant animals to obtain experimental data on the 
transplacental transfer of two prototypical environmental estrogens. Both 
daidzein and bisphenol A apparently cross the placenta, and a small part of 
the maternal dose will reach the fetus (Degen et al., 2002a; Bolt et al., 
2002). Secondly, it was of interest to compare i) the kinetics of these agents 
with each other and ii) with that of the test agents in non-pregnant animals. 
 
Studying the differences in the toxicokinetic behaviour due to pregnancy of 
the investigated organism we have to take into account the sparse data 
situation. As we deal with dynamic processes we have to consider that a 
tendency towards higher concentrations immediately after the application of 
a compound may change after some time. Thus, the different sampling times 
have to be investigated separately at first. If there seems to be just a shift in 
the concentration-time curve a global test may be applied summarizing the 
single Mann-Whitney U-tests.  
In the present data sets pregnant DA/Han rats seem to have lower plasma 
concentrations of daidzein or bisphenol A, respectively, than the non-preg-
nant animals only in the first (early) phase  after intravenous application of 
the compound. At – and for bisphenol A after – 120 minutes the situation 
seems to be reverse though it was not possible to confirm higher plasma 
concentrations in pregnant rats at a significance level of 0.05 or 0.1. With 
intravenous application, early time points of the concentration-time curves 
reflect mainly distribution and metabolism in the organisms, the later also 
elimination of metabolites. Major differences in these kinetic processes 
were not seen between pregnant and non-pregnant rats. Thus, we can 
conclude that metabolic inactivation by phase-II enzymes and subsequent 
elimination of our test agents is similarly efficient in both groups.  
With respect to the other point of interest, i.e. a comparison between 
bisphenol A and daidzein, we conclude that, at the same dose, elimination of 
the phytoestrogen is apparently more rapid than that of bisphenol A in both 
pregnant and non-pregnant rats. Neither this factor nor the higher ratio for 
plasma/fetus concentrations for bisphenol A than for daidzein will, however, 
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strongly impact on internal levels in light of the pronounced differences in 
exposure to these environmental estrogens. Human dietary intake estimates 
for bisphenol A are 	
– 50 mg for daidzein and the related 
isoflavone genistein (Degen, 2004). 
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